LCID
Lucid Group, Inc.
LCID's outlook is improving, though it still trails on the overall score.
SGHC
Super Group (SGHC) Limited
SGHC has the edge over LCID overall, supported by lower modeled downside and stronger valuation.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
SGHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Strong |
SGHC's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
SGHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 5.6x | $4.10 | -64% |
| Forward | 13x | $11.42 | — |
| Current | 16x | $11.42 | — |
| Fair | 23x | $16.77 | +47% |
| Expensive | 52x | $37.98 | +233% |
Historical ranges are pointers, not guarantees.
SGHC's PE is in its fair range at 16x. If earnings grow as analysts expect, today's price would be 13x next year's earnings, in its cheap range.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
SGHC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for SGHC, with profitability improving.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
SGHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.87 | +19% |
| Q2 2026 | $0.73 | +161% |
| Q1 2026 | $0.48 | +66% |
| Q4 2025 | $0.44 | +69% |
| Q3 2025 | $0.46 | +2200% |
| Q2 2025 | $0.28 | +1300% |
| Q1 2025 | $0.29 | +262% |
| Q4 2024 | $0.26 | +$0.28 |
| Q3 2024 | $0.02 | -80% |
SGHC has the edge over LCID on earnings quality, reporting a profit while its opponent remains loss making.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over SGHC on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
SGHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $684M | +0.3% |
| Q1 2026 | $612M | +8% |
| Q4 2025 | $578M | +21% |
| Q3 2025 | $555.7M | +11% |
| Q2 2025 | $681.7M | +48% |
| Q1 2025 | $566.8M | +24% |
| Q4 2024 | $476.5M | +19% |
| Q3 2024 | $499.8M | +26% |
SGHC's revenue has grown year over year for 14 quarters in a row: $684M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 25% | +7 points |
| Q1 2026 | 20% | +2.7 points |
| Q4 2025 | 17% | -4.2 points |
| Q3 2025 | 25% | +20 points |
| Q2 2025 | 18% | +4.5 points |
| Q1 2025 | 17% | +12 points |
| Q4 2024 | 22% | +23 points |
| Q3 2024 | 5.5% | -2.3 points |
SGHC has the edge over LCID on profitability, with a higher operating margin.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
SGHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $164M | +$286.3M |
| Q1 2026 | $89M | -63% |
| Q4 2025 | $0 | $0 |
| Q3 2025 | $0 | $0 |
| Q2 2025 | -$122.3M | -$122.3M |
| Q1 2025 | $241M | +$241M |
| Q4 2024 | $0 | $0 |
| Q3 2024 | $0 | $0 |
SGHC has the edge over LCID on cash generation, producing positive trailing cash flow while its opponent burns cash.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
SGHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.5% | +2.8M shares |
| 1 year | +1.9% | +9.3M shares |
| 3 years | +2.2% | +11.2M shares |
| 5 years | +4.6% | +22.4M shares |
SGHC has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
SGHC hasn't bought back shares in the past year.
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SGHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.7x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.8x | Net Cash |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -0.9x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.1x | Net Cash |
| Q3 2024 | -1.8x | Net Cash |
SGHC has more cash than debt.
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
SGHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 19.2 | Oversold |
SGHC's weekly RSI is 42 (neutral) and its Stochastic is 19 (oversold).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
SGHC PE vs Consumer Cyclical Sector
| Metric | SGHC | Sector median | Relative |
|---|---|---|---|
| PE | 16x | 18x | 13% below |
| PE % | 34 | 49 | 15 pts below |
SGHC is trading at 16x earnings, a 13% discount to the Consumer Cyclical sector's median of 18x.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
LCID is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
SGHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.2 | 1.6% above |
| 20 week MA | $12.8 | 11% below |
| 50 week MA | $12.0 | 4.6% below |
| 100 week MA | $10.8 | 6.1% above |
| 200 week MA | $7.19 | 59% above |
SGHC has the edge over LCID on trend strength, trading above more of its moving averages.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
SGHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.73 | $10.2 | +4.6% |
| 2021 | $10.2 | $9.96 | -2.2% |
| 2022 | $9.96 | $2.96 | -70% |
| 2023 | $2.96 | $3.17 | +7.1% |
| 2024 | $3.17 | $6.10 | +92% |
| 2025 | $6.10 | $11.9 | +95% |
| 2026 YTD | $11.9 | $11.4 | -4.2% |
SGHC has the edge over LCID on returns for 2026, with the stronger performance.